Strategic Focus Teligent remains a specialty generic pharmaceutical player with a focus on Topical, Injectable, Complex and Ophthalmic markets, indicating opportunities to cross-sell niche formulations and complex generics to expand product portfolio.

Manufacturing Expansion The company is expanding its New Jersey site to include sterile injectable, isolator-based manufacturing and expanded topical production, signaling capacity for new product introductions and potential manufacturing collaborations or toll manufacturing partnerships.

Financial Realities Past restructuring activity, debt financing and asset sales suggest financial volatility; potential sales motions should consider long-term value propositions, risk-sharing arrangements, and carefully staged contracts aligned with cash flow considerations.

Turnaround Opportunities History of headcount reductions and leadership changes, including a chief restructuring officer, indicates an opportunity to engage on efficiency-focused supply deals, inventory optimization, and strategic partnerships to accelerate turnaround.

Global footprint Operations in Canada and Estonia alongside a U.S. base, plus prior asset sales, point to potential for regional supply collaborations, regulatory-compliant import/export arrangements, and multi-region distribution strategies.